The US FDA has approved mitapivat (Aqvesme), the first oral pill designed to treat anemia in adults with thalassaemia, a genetic blood disorder. This milestone therapy addresses the disease at a cellular level, potentially improving hemoglobin levels and reducing the need for blood transfusions. While not yet available in India, specialists believe this oral treatment could significantly transform the quality of life and long-term outcomes for thalassaemia patients globally.